Real-world onabotulinumtoxinA treatment patterns in patients with overactive bladder.

Bilal ChughtaiChristine N RickerRyan J Boldt Dean S Elterman

Published in: Neurourology and urodynamics (2023)

Early discontinuation of onabotulinumtoxinA therapy for OAB is common and most discontinuers do not receive alternative treatments. Providers have the opportunity to educate OAB patients with un- or undertreated symptoms regarding alternative options.

Keyphrases